UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves

Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds.

On January 26, UBS lifted its terms people connected Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy standing connected the stock. The telephone reflects a much constructive presumption connected the broader US pharma and biotech space. UBS expects the radical to clasp up good this year. Valuations are inactive appealing, capitalist positioning remains light, and immoderate of the unit astir cause pricing has started to ease. Add successful dependable pharma-led M&A activity, which often spills implicit into biotech, and the setup looks supportive. Even with worries that guidance could crook cautious aft the caller rally, UBS argues that large pharma and biotech inactive look inexpensive capable to support wealth flowing into the sector.

Earlier this month, Amgen CEO Bob Bradway spoke with CNBC’s Jim Cramer and shared his optimism astir the company’s obesity drug. He said semipermanent value absorption is 1 of the hardest challenges successful this space, and that is wherever Amgen believes it tin marque a difference.

On January 12, Amgen said a proceedings of its experimental GLP-1 drug, MariTide, showed patients were capable to support value nonaccomplishment for up to 2 years with a monthly injection. That stands out, since astir weight-loss drugs connected the marketplace contiguous are taken weekly.

Bradway told Cramer the institution believes MariTide could yet beryllium dosed monthly oregon adjacent little often. He pointed to aboriginal information suggesting a quarterly enactment whitethorn beryllium possible. Amgen is besides investigating a scope of doses to fig retired what works champion implicit the agelong haul. As Bradway enactment it, keeping patients connected therapy is critical. Persistence, helium said, is everything.

He besides commented connected Amgen’s acquisition of Horizon Therapeutics, noting that the woody has been moving good truthful far. According to Bradway, Horizon fits people with Amgen’s strengths, peculiarly successful biologics and autoimmune diseases.

Amgen Inc. (NASDAQ:AMGN) is simply a biotechnology institution that develops, manufactures, and delivers medicines aimed astatine immoderate of the astir challenging diseases, with a absorption connected areas wherever aesculapian needs stay high.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Dividend Stocks with Over 8% Yield and Retirement Stock Portfolio: 12 Low Risk Investments

Disclosure: None.